MX2016006807A - Derivados de imidazol. - Google Patents

Derivados de imidazol.

Info

Publication number
MX2016006807A
MX2016006807A MX2016006807A MX2016006807A MX2016006807A MX 2016006807 A MX2016006807 A MX 2016006807A MX 2016006807 A MX2016006807 A MX 2016006807A MX 2016006807 A MX2016006807 A MX 2016006807A MX 2016006807 A MX2016006807 A MX 2016006807A
Authority
MX
Mexico
Prior art keywords
imidazole derivatives
imidazole
derivatives
compounds
formula
Prior art date
Application number
MX2016006807A
Other languages
English (en)
Inventor
Flohr Alexander
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of MX2016006807A publication Critical patent/MX2016006807A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invención se refiere a compuestos de la fórmula (I), (ver Fórmula) en la que A, B, R1 y R2 son como se definió aquí antes.
MX2016006807A 2013-11-28 2014-11-25 Derivados de imidazol. MX2016006807A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP13194931 2013-11-28
PCT/EP2014/075469 WO2015078836A1 (en) 2013-11-28 2014-11-25 Imidazole derivatives

Publications (1)

Publication Number Publication Date
MX2016006807A true MX2016006807A (es) 2016-09-07

Family

ID=49667067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016006807A MX2016006807A (es) 2013-11-28 2014-11-25 Derivados de imidazol.

Country Status (10)

Country Link
US (1) US9586970B2 (es)
EP (1) EP3074387B1 (es)
JP (1) JP2017501135A (es)
KR (1) KR20160089474A (es)
CN (1) CN105793256B (es)
AR (1) AR098528A1 (es)
CA (1) CA2930293A1 (es)
MX (1) MX2016006807A (es)
RU (1) RU2016123329A (es)
WO (1) WO2015078836A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020013697A2 (pt) 2018-11-06 2020-12-01 H. Lundbeck A/S compostos para tratamento de sintomas negativos e comprometimentos cognitivos
WO2020094591A1 (en) 2018-11-06 2020-05-14 H. Lundbeck A/S Pde10a inhibitors for treating negative symptoms and cognitive impairments in a patient suffering from schizophrenia
EP4069685A1 (en) 2019-12-02 2022-10-12 F. Hoffmann-La Roche AG Alkynyl-(heteroaryl)-carboxamide hcn1 inhibitors

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2342191B1 (en) * 2008-09-10 2013-03-20 Mitsubishi Tanabe Pharma Corporation Aromatic nitrogen-containing 6-membered ring compounds and their use
TWI487705B (zh) * 2009-12-17 2015-06-11 Lundbeck & Co As H 作為ｐｄｅ１０ａ酵素抑制劑之雜芳香族芳基三唑衍生物
JP5911476B2 (ja) * 2010-05-26 2016-04-27 スノビオン プハルマセウトイカルス インコーポレイテッド ヘテロアリール化合物及びその使用方法
WO2012096929A2 (en) * 2011-01-11 2012-07-19 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof

Also Published As

Publication number Publication date
KR20160089474A (ko) 2016-07-27
US20160264585A1 (en) 2016-09-15
CA2930293A1 (en) 2015-06-04
AR098528A1 (es) 2016-06-01
EP3074387A1 (en) 2016-10-05
EP3074387B1 (en) 2017-11-08
HK1223621A1 (zh) 2017-08-04
US9586970B2 (en) 2017-03-07
WO2015078836A1 (en) 2015-06-04
CN105793256B (zh) 2019-09-10
RU2016123329A (ru) 2018-01-10
JP2017501135A (ja) 2017-01-12
CN105793256A (zh) 2016-07-20

Similar Documents

Publication Publication Date Title
PH12016500676B1 (en) Pyrimidine fgfr4 inhibitors
EA201590321A1 (ru) Дейтерированный барицитиниб
PH12015502546B1 (en) 3-(4-isobutyl-2-methylphenyl) propanal as perfume ingredient
UA118666C2 (uk) Похідні піразолу
IN2015DN00598A (es)
PH12015501933B1 (en) Novel pyridine derivatives
MX364069B (es) Moduladores de la proteína activadora de 5-lipoxigenasa.
JO3318B1 (ar) مثبطات bace
MY180050A (en) Novel purine derivatives
MX2015008829A (es) Momelotinib deuterado.
PH12015502462A1 (en) Imidazo-triazine derivatives as pde10 inhibitors
MX2016004393A (es) Derivados de carboxamida como compuestos pesticidas.
CY1121116T1 (el) Νεα μεθοδος για την συνθεση αγομελατινης
MX2015014470A (es) Analogos de combretastatina.
MX2015016766A (es) Nuevos derivados de tetrazolona.
MX2016006807A (es) Derivados de imidazol.
MX2015009377A (es) Compuestos radiomarcados.
IN2013MU01219A (es)
MX2015012610A (es) Pacritinib deuterizado.
TW201613924A (en) (Hetero)aryl imidazoles/pyrazoles
UA89428U (en) 2-(14,15-dioxa-7-azadispirro[5,1,5,2]pentadec -7-yl)ethanol
UA86107U (ru) Пиперазиния 1-н-бутилтеобромин-8-илтиоацетат, который проявляет диуретическое действие
UA91886U (uk) 1-трет-бутокси-3-(2,2,6,6-тетраметил-4-гідроксипіперидино)-2-пропанол
UA87254U (ru) Соединение 1,1-диэтилкарбокси-2-метокси-2-трифторметилэтилен с потенциальными физиологическими свойствами
UA89447U (ru) Соединение 1,1-диэтилкарбокси-2-хлор-2-трифторметилэтилен с потенциальными физиологическими свойствами